Article

September 23, 2022

AJMC® in the Press, September 23, 2022

Author(s):

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article by MIT Technology Review referenced a study published in the January 2019 Health Information Technology special issue of The American Journal of Managed Care^®. The study, “Drivers of Health Information Exchange Use During Postacute Care Transitions,” showed that health information exchange offers significant potential to address unmet informational needs during transitions between hospitals and skilled nursing facilities, but workflow barriers and design limitations currently limit its value.

Related Videos

Tiara Green, MSEd

Ryan Jacobs, MD, Atrium Health Levine Cancer Institute

Kelly Harris, APRN

Jessica K. Paulus, ScD, Ontada

Rachel Dalthorp, MD

Jessica K. Paulus, ScD, Ontada

Michael Thorpy, MD

Sindhuja Kadambi, MD, MS

Matthew Callister, MD

Rachel Dalthorp, MD

Related Content

SMA spinal muscular atrophy | Image Credit: © Rochu_2008 - stock.adobe.com

July 26th 2024

Potential Biomarkers Predict Disease Severity and Treatment Response in SMA

Results from a single-center, observational, prospective study suggested that inflammatory markers could predict disease severity and treatment efficacy for patients with spinal muscular atrophy (SMA).

Managed Care Cast: Frameworks for Advancing Health Equity

July 23rd 2024

Frameworks for Advancing Health Equity: Health Equity by Design

Giuliana Grossi

Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

A trio of experts discuss the challenges of diagnosing and managing paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening disorder.

Efanesoctocog alfa is a high-sustained factor VIII replacement therapy for the treatment of hemophilia A | image credit: Ekaterina - stock.adobe.com

July 25th 2024

Efanesoctocog Alfa Prophylaxis Promising for Pediatric Severe Hemophilia A

The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa prophylaxis.

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School

July 24th 2024

Examining Trends, Future Directions in AI and Health Care

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School, discusses current and future uses in digital health care.

Related Content

SMA spinal muscular atrophy | Image Credit: © Rochu_2008 - stock.adobe.com

July 26th 2024

Potential Biomarkers Predict Disease Severity and Treatment Response in SMA

Results from a single-center, observational, prospective study suggested that inflammatory markers could predict disease severity and treatment efficacy for patients with spinal muscular atrophy (SMA).

Managed Care Cast: Frameworks for Advancing Health Equity

July 23rd 2024

Frameworks for Advancing Health Equity: Health Equity by Design

Giuliana Grossi

Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

A trio of experts discuss the challenges of diagnosing and managing paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening disorder.

Efanesoctocog alfa is a high-sustained factor VIII replacement therapy for the treatment of hemophilia A | image credit: Ekaterina - stock.adobe.com

July 25th 2024

Efanesoctocog Alfa Prophylaxis Promising for Pediatric Severe Hemophilia A

The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa prophylaxis.

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School

July 24th 2024

Examining Trends, Future Directions in AI and Health Care

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School, discusses current and future uses in digital health care.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions